# Doxorubicin

## Doxor lyo inj 10mg (凍晶)

##### 臨採

| TAH Drug Code      | [IDOX](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IDOX)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Acute and chronic leukocytosis, sarcoma, lymphoma, fibrosarcoma, neuroblastoma, breast cancer, lung cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | Administer by intravenous injection or, for local tumor treatment, slow infusion through the local artery or instillation into the bladder via catheter. Dissolve using provided solvent. Do not administer orally, or via intramuscular or intrathecal injection. [Intravenous Injection] The cumulative dose of intravenous doxorubicin should not exceed 550 mg/m2. Monotherapy: (Adults) 60-75 mg/m2 IVD every 21 days. (Elderly or immunocompromised) 60 mg/m2 IVD every 21 days. (Pediatric) 30 mg/m2 IVD, administered daily for three consecutive days, repeated every 4 weeks. Combination Therapy: (With bone marrow suppressants) 25-50 mg/m2 IVD every 3-4 weeks. (Without bone marrow suppressants) 60-75 mg/m2 IVD every 3-4 weeks. [Intravesical Administration] Instill 30-50 mg into the bladder let it stay for 1-2 hours every 1 week to 1 month. Recommended concentration: 1 mg/mL. Rotate body during instillation for optimal contact. Instruct patients not to drink liquids 12 hours before to avoid dilution. Prompt voiding after instillation. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Allergic reaction to the main ingredient or other excipients. Allergic reaction to other anthracyclines or anthracenediones. Intravenous injection use: Previous persistent bone marrow suppression caused by other antineoplastic drugs or radiation therapy. Severe hepatic dysfunction. Severe myocardial dysfunction. Recent myocardial infarction. Severe arrhythmias. Previous treatment with the maximum cumulative dose of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones. Intravesical use: Urethral infection. Bladder inflammation. Hematuria.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Common: Alopecia (92%), Nausea (>10%), Vomiting (34-37%) Serious: Cardiomyopathy, Congestive heart failure, Left ventricular failure, acute, Myocardial infarction, Myocarditis, Pericarditis, Tachyarrhythmia, Injection site extravasation, Radiation recall reaction due to cytotoxic therapy, Tissue necrosis, Pancreatitis, Acute myeloid leukemia, Leukopenia, Grade 3 or 4 (3.7%), Myelodysplastic syndrome, Myelosuppression, Neutropenia, Thrombocytopenia, Grade 3 or 4 (0.1%), Hepatitis, Veno-occlusive disease of the liver, Anaphylaxis, Septic shock (2%), Radiation pneumonitis, Tumor lysis syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

## Lipo-Dox inj 20mg (自費用)

| TAH Drug Code      | [ILIPD](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ILIPD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of AIDS-related Kaposi's sarcoma in patients with low CD4 (< 200 CD4 lymphocytes/mm3) & diseases in mucosa, skin & internal organs. Treatment of metastasis carcinoma of the ovary in patients with disease that is recurrent to both 1st-line platinum- & paclitaxel-based chemotherapy regimens. As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | [Breast cancer/Ovarian cancer] 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.[Multiple myeloma] 30 mg/m2 on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. The dose should be repeated as long as patients respond satisfactorily and tolerate treatment. Day 4 dosing of both medicinal products may be delayed up to 48 hours as medically necessary. Doses of bortezomib should be at least 72 hours apart. [AIDS-related Kaposi sarcoma (AIDS-KS)] 20 mg/m2 once every 2-3 weeks for 2-3 months is recommended to achieve a therapeutic response. Continue treatment as needed to maintain a therapeutic response. Avoid intervals shorter than 10 days. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Severe hypersensitivity (including anaphylaxis) to doxorubicin liposomal, conventional doxorubicin, or any component of the formulation. Breast-feeding. AIDS-KS patients effectively treat with local or systemic α-interferon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adverse Effects    | Infusion-associated acute reactions, stomatitis, Palmar-plantar erythrodysesthesia, cardiac toxicity. Nausea, leukopenia, neutropenia, anemia & thrombocytopenia. Asthenia, alopecia, fever, diarrhea. Resp infections, laboratory abnormalities.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

## Lipo-Dox inj 20mg (健保用)

| TAH Drug Code      | [ILIPD1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ILIPD1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of AIDS-related Kaposi's sarcoma in patients with low CD4 (< 200 CD4 lymphocytes/mm3) & diseases in mucosa, skin & internal organs. Treatment of metastasis carcinoma of the ovary in patients with disease that is recurrent to both 1st-line platinum- & paclitaxel-based chemotherapy regimens. As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | [Breast cancer/Ovarian cancer] 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment. [Multiple myeloma] 30 mg/m2 on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. The dose should be repeated as long as patients respond satisfactorily and tolerate treatment. Day 4 dosing of both medicinal products may be delayed up to 48 hours as medically necessary. Doses of bortezomib should be at least 72 hours apart. [AIDS-related Kaposi sarcoma (AIDS-KS)] 20 mg/m2 once every 2-3 weeks for 2-3 months is recommended to achieve a therapeutic response. Continue treatment as needed to maintain a therapeutic response. Avoid intervals shorter than 10 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | Severe hypersensitivity (including anaphylaxis) to doxorubicin liposomal, conventional doxorubicin, or any component of the formulation. Breast-feeding. AIDS-KS patients effectively treat with local or systemic α-interferon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Infusion-associated acute reactions, stomatitis, Palmar-plantar erythrodysesthesia, cardiac toxicity. Nausea, leukopenia, neutropenia, anemia & thrombocytopenia. Asthenia, alopecia, fever, diarrhea. Resp infections, laboratory abnormalities. Dermatologic: Alopecia, Hand-foot syndrome due to cytotoxic therapy (ovarian cancer, 50.6% AIDS-related Kaposi's sarcoma, 3.4% multiple myeloma, 19% ), Rash (ovarian cancer, 28.5%AIDS-related Kaposi's sarcoma, 1% to 5% multiple myeloma, 22% ) Gastrointestinal: Constipation (multiple myeloma, 31% ), Diarrhea (ovarian cancer, 20.9%AIDS-related Kaposi's sarcoma, 7.8%multiple myeloma, 46% ), Loss of appetite (ovarian cancer, 20.1% AIDS-related Kaposi's sarcoma, 1% to 5%multiple myeloma, 19% ), Nausea (ovarian cancer, 46% AIDS-related Kaposi's sarcoma, 16.9%multiple myeloma, 48% ), Stomatitis (ovarian cancer, 41.4% AIDS-related Kaposi's sarcoma, 6.8%multiple myeloma, 20% ), Vomiting (ovarian cancer, 32.6%AIDS-related Kaposi's sarcoma, 7.8%multiple myeloma, 32%) Hematologic: Decreased platelet count (ovarian cancer, 13% to 24.2%; AIDS-related Kaposi's sarcoma, 60.9%; multiple myeloma, 33%), Hemoglobin low (ovarian cancer, 40.2% to 52.6%; AIDS-related Kaposi's sarcoma, 55.4%; multiple myeloma, 25% ), Neutrophil count abnormal (ovarian cancer, 19% to 35.1%; AIDS-related Kaposi's sarcoma, 48.9%; multiple myeloma, 36%) Neurologic: Asthenia (ovarian cancer, 40.2% AIDS-related Kaposi's sarcoma, 9.9% multiple myeloma, 22% ) Psychiatric: Fatigue (multiple myeloma, 36%; ) Other: Drug fever (ovarian cancer, 21.3%AIDS-related Kaposi's sarcoma, 9.1%multiple myeloma, 31% ) |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

